胆汁淤积性肝病的升行性病理生理学
本文综述提出胆汁淤积性肝病(尤以原发性胆汁性胆管炎和原发性硬化性胆管炎为代表)随时间呈解剖学上「升行性」演进:早期病变位于下游胆管,继而胆汁淤积导致上游肝实质受胆汁盐介导的毒性损伤;据此作者主张按疾病阶段分层用药,并呼吁优先开发可定义疾病阶段的生物标志物。
要点
- 胆汁淤积性肝病的早期病变位于下游胆管,继而引起上游肝实质的胆汁盐毒性损伤。
- 胆汁盐在高浓度下具有毒性,胆管网络与胆囊内即存在此浓度,胆汁漏出可能是毒性驱动因素。
- 靶向胆汁盐毒性的药物在原发性胆汁性胆管炎中仅约50%-60%患者有效,原发性硬化性胆管炎尚无有效疗法。
核心结论
- 作者提出胆汁淤积性肝病的病理生理呈升行性演进,即早期病变位于下游胆管,胆汁淤积继而造成上游肝实质的胆汁盐介导毒性损伤。
- 作者认为这些观点可能有助于更好地对疾病进行分层,并就临床试验中新疗法的更「量身」使用提出建议。
- 作者指出疾病阶段定义性生物标志物仍缺乏,本综述意在呼吁优先开发有助于更好地分层这些疾病的生物标志物。
研究设计与样本
- 本文为综述,围绕原发性胆汁性胆管炎与原发性硬化性胆管炎的病理生理提出升行性演进的观点。
主要发现
- 胆汁盐在高浓度下具有毒性,此类浓度存在于胆小管网络、胆管与胆囊中,胆汁从该网络与胆管漏出可能是毒性的重要驱动因素。
- 肝脏对胆汁淤积有很强的适应能力,这可能促成临床上常观察到的症状轻微的变异间期。
- 靶向胆汁盐毒性的药物在原发性胆汁性胆管炎患者中仅约50%-60%有效,原发性硬化性胆管炎则尚无有效疗法。
关键数值与推荐
- 减少肠道胆汁盐吸收的顶膜钠依赖性胆汁盐转运体抑制剂降低胆汁盐负荷,最适合用于胆汁淤积患者。
- 抑制胆汁盐合成的药物(如法尼醇X受体激动剂)在最佳适应尚未建立时效果最大;当细胞色素P450 7A1表达已降低时,这些药物可能效果较差。
- 抗炎药物可能在早期疾病最有效,而拮抗胆汁盐毒性的药物(如熊去氧胆酸与去甲熊去氧胆酸)可能在各疾病阶段均有效。
- 原发性硬化性胆管炎的内镜下支架置入应保留用于并发胆汁淤积与胆管炎的情形,而非终末期疾病的胆汁淤积。
临床怎么用
- 作者认为这些论点支持考虑这些疾病的逐步式病理生理,并将治疗调整至疾病阶段。
- 作者认为减少肠道胆汁盐吸收的顶膜钠依赖性胆汁盐转运体抑制剂最适合用于胆汁淤积患者。
- 作者认为抑制胆汁盐合成的药物在最佳适应尚未建立时效果最大。
- 作者认为抗炎药物可能在早期疾病最有效,拮抗胆汁盐毒性的药物可能在各疾病阶段均有效。
- 作者认为原发性硬化性胆管炎的内镜下支架置入应保留用于并发胆汁淤积与胆管炎的情形,而非终末期疾病的胆汁淤积。
局限性
- 作者指出此类分层方法的一个障碍是疾病阶段定义性生物标志物仍然缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this review we develop the argument that cholestatic liver diseases, particularly primary biliary cholangitis and primary sclerosing cholangitis (PSC), evolve over time with anatomically an ascending course of the disease process. The first and early lesions are in "downstream" bile ducts. This eventually leads to cholestasis, and this causes bile salt (BS)-mediated toxic injury of the "upstream" liver parenchyma. BS are toxic in high concentration. These concentrations are present in the canalicular network, bile ducts, and gallbladder. Leakage of bile from this network and ducts could be an important driver of toxicity. The liver has a great capacity to adapt to cholestasis, and this may contribute to a variable symptom-poor interval that is often observed. Current trials with drugs that target BS toxicity are effective in only about 50%-60% of primary biliary cholangitis patients, with no effective therapy in PSC. This motivated us to develop and propose a new view on the pathophysiology of primary biliary cholangitis and PSC in the hope that these new drugs can be used more effectively. These views may lead to better stratification of these diseases and to recommendations on a more "tailored" use of the new therapeutic agents that are currently tested in clinical trials. Apical sodium-dependent BS transporter inhibitors that reduce intestinal BS absorption lower the BS load and are best used in cholestatic patients. The effectiveness of BS synthesis-suppressing drugs, such as farnesoid X receptor agonists, is greatest when optimal adaptation is not yet established. By the time cytochrome P450 7A1 expression is reduced these drugs may be less effective. Anti-inflammatory agents are probably most effective in early disease, while drugs that antagonize BS toxicity, such as ursodeoxycholic acid and nor-ursodeoxycholic acid, may be effective at all disease stages. Endoscopic stenting in PSC should be reserved for situations of intercurrent cholestasis and cholangitis, not for cholestasis in end-stage disease. These are arguments to consider a step-wise pathophysiology for these diseases, with therapy adjusted to disease stage. An obstacle in such an approach is that disease stage-defining biomarkers are still lacking. This review is meant to serve as a call to prioritize the development of biomarkers that help to obtain a better stratification of these diseases. (Hepatology 2017;65:722-738).
引用
- Jansen PL, Ghallab A, Vartak N, et al. The ascending pathophysiology of cholestatic liver disease. Hepatology. 2017. PMID: 27981592. doi:10.1002/hep.28965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。